7. AÑO Nº CASOS TASA DE INCIDENCIA
CRUDA (100,000)
2,000 1´050,346 34.944 (35.7)
2,020 1´621,140 43.424
2,050 2´484,916 55.634
CANCER DE MAMA
PROYECCION MUNDIAL
EPIDEMIOLOGIA
8. CANCER DE MAMA
PROYECCION EN EL PERU
AÑO Nº CASOS TASA DE INCIDENCIA
CRUDA (100,000)
2,000 3,155 24.384 (30.3)
2,020 5,643 33.122
2,050 9,734 45.519
9. Guidelines for International Breast Health and Cancer
Control–Implementation
Breast Cancer in Latin America
Results of the Latin American and Caribbean Society of Medical Oncology/Breast
Cancer Research Foundation Expert Survey
---------------------------------------------------------------------------------------------------
The incidence of breast cancer in Latin American countries is
lower than that in more developed countries, whereas the mortality
rate is higher. These differences probably are related to differences
in screening strategies and access to treatment.
Population-based data are needed to make informed decisions
Cancer 2008;113(8 suppl):2359–65. 2008 American Cancer Society
10. Currently, there are enormous differences in healthcare
expenditures between developed and developing countries;
developed countries spend nearly 10% of their gross domestic
product on healthcare, whereas poorer countries spend 5% to 6%
or less
Greater than 90% of countries had no national law or guideline
for mammography screening. The access rate to mammography
was 66.3% at the country level and 47% at the center level
Cancer 2008;113(8 suppl):2359–65. 2008 American Cancer Society
11. TABLE 2
Breast Cancer Screening and Diagnosis by Country and Center
Question Topic Answer % Country(n:95) % Center (n:100)
Access to mammography
All the population 66 47
High and medium
income 32 52
Low income 0 1
Unknown 2 0
Origin of initial diagnostic
suspicion
Patient 79 48
Physician 19 49
Screening 0 2
Unknown 2 1
First specialist consulted
upon suspicion
Breast cancer
surgeon or
gynecologist
83 82
Surgeon 4 4
Physician 13 9
Oncologist 0 5
Delay between mammographic or
clinical suspicion and
histopathologic confirmation
<1 mo 2 46
1-3 mo 60 45
>3 mo 32 7
Unknown 6 2
Cancer 2008;113(8 suppl):2359–65. 2008 American Cancer Society
12. TABLE 3
Treatment Related Survey Questions by Country and Center
Question Topic Answer % Country (n: 95) %
Center(n:100)
Delay from diagnosis to surgery or
primary systemic treatment
<1 mo 15 81
1-3 mo 76 18
>3 mo 6 0
Unknown 3 1
Delay from surgery to first treatment
(hormonal, QT, RT)
<1 mo 20 76
1-3 mo 69 22
>3 mo 5 1
Unknown 6 1
Cancer 2008;113(8 suppl):2359–65. 2008 American Cancer Society
13. CANCER DE MAMACANCER DE MAMA
•El cáncer de mama es la proliferación acelerada, desordenada
y no controlada de células pertenecientes a distintos tejidos de
una glándula mamaria
•Carcinoma, se aplica a los neoplasias malignas que se originan
en estirpes celulares de origen epitelial o glandular
•Sin embargo pueden existir degeneración de células de estirpe
mesenquimal (sarcomas), y otros órganos linfáticos
•Los carcinomas de mama suponen más del 95% de los tumores
malignos de las mamas,
14.
15.
16.
17. Proyección cráneo-caudal de una mama normal (según Gros).
1. Pezón; 2.Galactóforos; 3. Aréola; 4. Contorno de la piel; 5. Ligamentos de Cooper; 6. Lagos adiposos cuyo
conjunto (10) forma la capa grasa anterior; 7. Tejido glandular fibro-adiposo;8. Capa grasa retromamaria; 9.
Aponeurosis pectoral mayor.
Se permite
Health: salud Guidelines for International Breast Health and Cancer Control–Implementation : Las pautas para la Salud Internacional de Seno y Cáncer Controlan–Implementación -------------------------------------------- Survey : inspeccion
Actualmente, hay enormes diferencias en gastos de asistencia sanitaria entre desarrollado y los países endesarrollo; desarrolló países gastan casi 10% de su producto interno bruto en la asistencia sanitaria,mientras que países más pobres gastan 5% a 6% o menos
